Summary of results.

Therascreen does not include Q61 mutations or BRAF. One tumor had KRAS p.G13D and p.Q61R mutations, while a further tumor had BRAF p.V600E and KRAS p.G12V mutations. This table includes re-testing results in three tumors (orginal results in brackets), and dual mutations in two tumors. One tumor was called wild-type by castPCR, and mutant by Therascreen, with a mutation by both methods on re-testing. Two further tumors were called mutant by either castPCR or Therascreen: both were wild-type on re-testing.
Summary of results.